Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia

D. E. Joyner, T. A. Damron, A. Aboulafia, W. Bokor, J. D. Bastar, R Randall

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Recommendations have been advanced recently for the use of cancer/testis (CT) immunotherapy against sarcomas. CT antigens are encoded by cancer-germline genes (e.g., hMAGE family) that are expressed in tumors and male germline cells but typically not in normal tissues. At present, little information is available regarding CT expression in mesenchymal neoplasms, and it remains uncertain whether CT immunotherapy will serve as a viable alternative or adjunct to current sarcoma therapies involving resection, followed by adjuvant radiotherapy and/or chemotherapy. In this study, hMAGEA2, hMAGEA3, hMAGEA4, and hMAGEC1 mRNA content in 21 benign mesenchymal tumors (representing seven histotypes) and 28 primary sarcomas (10 histotypes) was inventoried using real-time-PCR and then compared against hMAGE mRNA expression in non-sarcomatous malignancies, three cell lines, and muscle. hMAGEA2, hMAGEA3, and hMAGEC1 transcripts were infrequent in mesenchymal tissues in general, whereas hMAGEA4 mRNA was present in 84% of all mesenchymal tumors, 100% of non-sarcomatous tumors, all three cell lines, and in four of five muscle samples. Although hMAGEA4 mRNA was detected in four of five muscle preparations, there was no indication that the mRNA was translated into protein. The presence of hMAGEA4 mRNA in muscle, plus the inconsistent and infrequent occurrence of hMAGEA2, hMAGEA3, and hMAGEC1 mRNA within and among mesenchymal tumor histotypes, makes these four hMAGE antigens unlikely candidates for sarcoma-specific immunotherapy.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalTissue Antigens
Volume68
Issue number1
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Melanoma-Specific Antigens
Testicular Neoplasms
Messenger RNA
Tumors
Sarcoma
Muscle
Neoplasms
Immunotherapy
Muscles
Cells
Tissue
Antigens
Cell Line
Adjuvant Radiotherapy
Chemotherapy
Neoplasm Genes
Radiotherapy
Adjuvant Chemotherapy
Real-Time Polymerase Chain Reaction
Genes

Keywords

  • hMAGE family
  • hMAGEA4 mRNA
  • Mesenchymal tissues
  • Real-time-PCR
  • Sarcoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Genetics

Cite this

Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia. / Joyner, D. E.; Damron, T. A.; Aboulafia, A.; Bokor, W.; Bastar, J. D.; Randall, R.

In: Tissue Antigens, Vol. 68, No. 1, 01.07.2006, p. 19-27.

Research output: Contribution to journalArticle

Joyner, D. E. ; Damron, T. A. ; Aboulafia, A. ; Bokor, W. ; Bastar, J. D. ; Randall, R. / Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia. In: Tissue Antigens. 2006 ; Vol. 68, No. 1. pp. 19-27.
@article{0e44ac638ada4a30b63cb7b7f0083cae,
title = "Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia",
abstract = "Recommendations have been advanced recently for the use of cancer/testis (CT) immunotherapy against sarcomas. CT antigens are encoded by cancer-germline genes (e.g., hMAGE family) that are expressed in tumors and male germline cells but typically not in normal tissues. At present, little information is available regarding CT expression in mesenchymal neoplasms, and it remains uncertain whether CT immunotherapy will serve as a viable alternative or adjunct to current sarcoma therapies involving resection, followed by adjuvant radiotherapy and/or chemotherapy. In this study, hMAGEA2, hMAGEA3, hMAGEA4, and hMAGEC1 mRNA content in 21 benign mesenchymal tumors (representing seven histotypes) and 28 primary sarcomas (10 histotypes) was inventoried using real-time-PCR and then compared against hMAGE mRNA expression in non-sarcomatous malignancies, three cell lines, and muscle. hMAGEA2, hMAGEA3, and hMAGEC1 transcripts were infrequent in mesenchymal tissues in general, whereas hMAGEA4 mRNA was present in 84{\%} of all mesenchymal tumors, 100{\%} of non-sarcomatous tumors, all three cell lines, and in four of five muscle samples. Although hMAGEA4 mRNA was detected in four of five muscle preparations, there was no indication that the mRNA was translated into protein. The presence of hMAGEA4 mRNA in muscle, plus the inconsistent and infrequent occurrence of hMAGEA2, hMAGEA3, and hMAGEC1 mRNA within and among mesenchymal tumor histotypes, makes these four hMAGE antigens unlikely candidates for sarcoma-specific immunotherapy.",
keywords = "hMAGE family, hMAGEA4 mRNA, Mesenchymal tissues, Real-time-PCR, Sarcoma",
author = "Joyner, {D. E.} and Damron, {T. A.} and A. Aboulafia and W. Bokor and Bastar, {J. D.} and R Randall",
year = "2006",
month = "7",
day = "1",
doi = "10.1111/j.1399-0039.2006.00618.x",
language = "English (US)",
volume = "68",
pages = "19--27",
journal = "HLA",
issn = "2059-2302",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia

AU - Joyner, D. E.

AU - Damron, T. A.

AU - Aboulafia, A.

AU - Bokor, W.

AU - Bastar, J. D.

AU - Randall, R

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Recommendations have been advanced recently for the use of cancer/testis (CT) immunotherapy against sarcomas. CT antigens are encoded by cancer-germline genes (e.g., hMAGE family) that are expressed in tumors and male germline cells but typically not in normal tissues. At present, little information is available regarding CT expression in mesenchymal neoplasms, and it remains uncertain whether CT immunotherapy will serve as a viable alternative or adjunct to current sarcoma therapies involving resection, followed by adjuvant radiotherapy and/or chemotherapy. In this study, hMAGEA2, hMAGEA3, hMAGEA4, and hMAGEC1 mRNA content in 21 benign mesenchymal tumors (representing seven histotypes) and 28 primary sarcomas (10 histotypes) was inventoried using real-time-PCR and then compared against hMAGE mRNA expression in non-sarcomatous malignancies, three cell lines, and muscle. hMAGEA2, hMAGEA3, and hMAGEC1 transcripts were infrequent in mesenchymal tissues in general, whereas hMAGEA4 mRNA was present in 84% of all mesenchymal tumors, 100% of non-sarcomatous tumors, all three cell lines, and in four of five muscle samples. Although hMAGEA4 mRNA was detected in four of five muscle preparations, there was no indication that the mRNA was translated into protein. The presence of hMAGEA4 mRNA in muscle, plus the inconsistent and infrequent occurrence of hMAGEA2, hMAGEA3, and hMAGEC1 mRNA within and among mesenchymal tumor histotypes, makes these four hMAGE antigens unlikely candidates for sarcoma-specific immunotherapy.

AB - Recommendations have been advanced recently for the use of cancer/testis (CT) immunotherapy against sarcomas. CT antigens are encoded by cancer-germline genes (e.g., hMAGE family) that are expressed in tumors and male germline cells but typically not in normal tissues. At present, little information is available regarding CT expression in mesenchymal neoplasms, and it remains uncertain whether CT immunotherapy will serve as a viable alternative or adjunct to current sarcoma therapies involving resection, followed by adjuvant radiotherapy and/or chemotherapy. In this study, hMAGEA2, hMAGEA3, hMAGEA4, and hMAGEC1 mRNA content in 21 benign mesenchymal tumors (representing seven histotypes) and 28 primary sarcomas (10 histotypes) was inventoried using real-time-PCR and then compared against hMAGE mRNA expression in non-sarcomatous malignancies, three cell lines, and muscle. hMAGEA2, hMAGEA3, and hMAGEC1 transcripts were infrequent in mesenchymal tissues in general, whereas hMAGEA4 mRNA was present in 84% of all mesenchymal tumors, 100% of non-sarcomatous tumors, all three cell lines, and in four of five muscle samples. Although hMAGEA4 mRNA was detected in four of five muscle preparations, there was no indication that the mRNA was translated into protein. The presence of hMAGEA4 mRNA in muscle, plus the inconsistent and infrequent occurrence of hMAGEA2, hMAGEA3, and hMAGEC1 mRNA within and among mesenchymal tumor histotypes, makes these four hMAGE antigens unlikely candidates for sarcoma-specific immunotherapy.

KW - hMAGE family

KW - hMAGEA4 mRNA

KW - Mesenchymal tissues

KW - Real-time-PCR

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=33745157163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745157163&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0039.2006.00618.x

DO - 10.1111/j.1399-0039.2006.00618.x

M3 - Article

C2 - 16774536

AN - SCOPUS:33745157163

VL - 68

SP - 19

EP - 27

JO - HLA

JF - HLA

SN - 2059-2302

IS - 1

ER -